Marja Vääräsmäki

Prof. Marja Vääräsmäki

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2000 in Early Human Development
Verified
Journal Article
Closed access
MVMarja Vääräsmäki
Marja Vääräsmäki
AHAnna-Liisa Hartikainen
Anna-Liisa Hartikainen
MAMarjatta Anttila
Marjatta Anttila
SPSirkka Pramila
Sirkka Pramila
MKMaila Koivisto
Maila Koivisto

26 February 2022 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
NPNatalia Pervjakova
Natalia Pervjakova
GMGunn-Helen Moen
Gunn-Helen Moen
MBMaria-Carolina Borges
Maria-Carolina Borges
TFTeresa Ferreira
Teresa Ferreira
JCJames P Cook
James P Cook
RMReedik Mägi
Reedik Mägi
Gestational diabetes mellitus (GDM) is associated with increased risk of pregnancy complications and adverse perinatal outcomes. GDM often reoccurs and is associated with increased risk of subsequent diagnosis of type 2 diabetes (T2D). To improve our understanding of the aetiological factors and molecular processes driving the occurrence of GDM, including the extent to which these overlap with T2D pathophysiology, the GENetics of Diabetes In Pregnancy Consortium assembled genome-wide association studies of diverse ancestry in a total of 5485 women with GDM and 347 856 without GDM. Through multi-ancestry meta-analysis, we identified five loci with genome-wide significant association (P < 5 × 10−8) with GDM, mapping to/near MTNR1B (P = 4.3 × 10−54), TCF7L2 (P = 4.0 × 10−16), CDKAL1 (P = 1.6 × 10−14), CDKN2A-CDKN2B (P = 4.1 × 10−9) and HKDC1 (P = 2.9 × 10−8). Multiple lines of evidence pointed to the shared pathophysiology of GDM and T2D: (i) four of the five GDM loci (not HKDC1) have been previously reported at genome-wide significance for T2D; (ii) significant enrichment for associations with GDM at previously reported T2D loci; (iii) strong genetic correlation between GDM and T2D and (iv) enrichment of GDM associations mapping to genomic annotations in diabetes-relevant tissues and transcription factor binding sites. Mendelian randomization analyses demonstrated significant causal association (5% false discovery rate) of higher body mass index on increased GDM risk. Our results provide support for the hypothesis that GDM and T2D are part of the same underlying pathology but that, as exemplified by the HKDC1 locus, there are genetic determinants of GDM that are specific to glucose regulation in pregnancy.

24 November 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
EPElisa Paavilainen
Elisa Paavilainen
KTKristiina Tertti
Kristiina Tertti
HNHilkka Nikkinen
Hilkka Nikkinen
RVRiitta Veijola
Riitta Veijola
MVMarja Vääräsmäki
Marja Vääräsmäki
HNHarri Niinikoski
Harri Niinikoski
Aims: To compare anthropometrics, and lipid and glucose metabolism in the 9‐year‐old offspring of mothers treated with metformin or insulin for gestational diabetes mellitus (GDM). Materials and Methods: This was a Finnish two‐centre, 9‐year follow‐up study of two open‐label, randomized controlled trials comparing the effects observed in the offspring of mothers who received metformin and insulin treatment for GDM. Measurements included anthropometrics, blood pressure, lipoproteins, and oral glucose tolerance tests. This study was registered with ClinicalTrials.gov , number NCT02417090. Results: At the age of 9 years 172 children (55% of the original study cohort, 82 from the metformin and 90 from the insulin group) participated in the study. No differences were found between the 9‐year‐old offspring groups in anthropometric variables, including body mass index and waist‐to‐height ratio. The offspring in the metformin group had higher high‐density lipoprotein (HDL) cholesterol concentrations (1.72 vs. 1.54 mmol/L; P = 0.039) but lower low‐density lipoprotein cholesterol (2.39 vs. 2.58 mmol/L; P = 0.046) and apolipoprotein B concentrations (0.63 vs. 0.67 g/L; P = 0.043) than the offspring in the insulin group. The difference in HDL cholesterol concentration was found to be significant only in boys ( P = 0.003). The 2‐hour glucose value in the oral glucose tolerance test was 0.6‐mmol/L lower in boys from the metformin group than in those from the insulin group ( P = 0.015). Conclusions: Metformin treatment for GDM is associated with similar offspring growth and glucose metabolism but a more favourable lipid profile at the age of 9 years as compared to insulin treatment.

31 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNiina Sissala
Niina Sissala
SMSanna Mustaniemi
Sanna Mustaniemi
EKEero Kajantie
Eero Kajantie
MVMarja Vääräsmäki
Marja Vääräsmäki
PKPeppi Karppinen
Peppi Karppinen
Incidence of gestational diabetes (GDM) has increased rapidly. It poses significant risks for both mother and fetus affecting also negatively their longer-term metabolic heath. We asked whether early pregnancy maternal hemoglobin (Hb) levels, indicative for tissue oxygenation, would affect mother’s metabolic health and fetal outcome. We assessed in FinnGeDi, a Finnish multicenter case–control study for GDM (n = 1828), association of maternal 1st trimester Hb levels with metabolic parameters and perinatal outcome. Our data show that mothers with GDM had higher Hb levels compared to controls (mean difference 1.746 g/L). Hb levels associated positively with pre-pregnancy body mass index (BMI), fasting glucose levels and glucose levels in a glucose tolerance test and systolic and diastolic blood pressure (bp) levels. When assessed in quartiles the highest Hb quartile had more chronic and gestational hypertension and the most adverse outcome of the metabolic parameters, dose-dependency seen in bp, BMI and glucose levels. In a multivariable regression analysis Hb levels remained an independently associated parameter for GDM after adjusting for key covariates (OR 1.019, 95% CI [1.007; 1.031]). In conclusion, higher maternal Hb levels within the normal variation are an independent risk factor for GDM in this population but have little effect on perinatal outcome.

6 May 2020 in International Journal of Epidemiology
Verified
Journal Article
Open access
EKElina Keikkala
Elina Keikkala
SMSanna Mustaniemi
Sanna Mustaniemi
SKSanna Koivunen
Sanna Koivunen
JKJenni Kinnunen
Jenni Kinnunen
MVMatti Viljakainen
Matti Viljakainen
MVMarja Vääräsmäki
Marja Vääräsmäki

28 June 2002 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
MVMarja Vääräsmäki
Marja Vääräsmäki
MGM. Gissler
M. Gissler
ARA. Ritvanen
A. Ritvanen
AHA.‐L. Hartikainen
A.‐L. Hartikainen